192 related articles for article (PubMed ID: 30228815)
1. SHMT2 Overexpression Predicts Poor Prognosis in Intrahepatic Cholangiocarcinoma.
Ning S; Ma S; Saleh AQ; Guo L; Zhao Z; Chen Y
Gastroenterol Res Pract; 2018; 2018():4369253. PubMed ID: 30228815
[TBL] [Abstract][Full Text] [Related]
2. High Expression of Serine Hydroxymethyltransferase 2 Indicates Poor Prognosis of Gastric Cancer Patients.
Shi H; Fang X; Li Y; Zhang Y
Med Sci Monit; 2019 Oct; 25():7430-7438. PubMed ID: 31581160
[TBL] [Abstract][Full Text] [Related]
3. Prognostic and therapeutic value of mitochondrial serine hydroxyl-methyltransferase 2 as a breast cancer biomarker.
Zhang L; Chen Z; Xue D; Zhang Q; Liu X; Luh F; Hong L; Zhang H; Pan F; Liu Y; Chu P; Zheng S; Lou G; Yen Y
Oncol Rep; 2016 Nov; 36(5):2489-2500. PubMed ID: 27666119
[TBL] [Abstract][Full Text] [Related]
4. Flotillin-2 predicts poor prognosis and promotes tumor invasion in intrahepatic cholangiocarcinoma.
Xu Z; Wang T; Song H; Jiang X
Oncol Lett; 2020 Mar; 19(3):2243-2250. PubMed ID: 32194722
[TBL] [Abstract][Full Text] [Related]
5. High expression of SHMT2 is correlated with tumor progression and predicts poor prognosis in gastrointestinal tumors.
Liu Y; Yin C; Deng MM; Wang Q; He XQ; Li MT; Li CP; Wu H
Eur Rev Med Pharmacol Sci; 2019 Nov; 23(21):9379-9392. PubMed ID: 31773687
[TBL] [Abstract][Full Text] [Related]
6. Increased Expression of Serine Hydroxymethyltransferase 2 (SHMT2) is a Negative Prognostic Marker in Patients with Hepatocellular Carcinoma and is Associated with Proliferation of HepG2 Cells.
Ji L; Tang Y; Pang X; Zhang Y
Med Sci Monit; 2019 Aug; 25():5823-5832. PubMed ID: 31379360
[TBL] [Abstract][Full Text] [Related]
7. CUL4A overexpression as an independent adverse prognosticator in intrahepatic cholangiocarcinoma.
Huang G-; Liu TT; Weng SW; You HL; Wei YC; Chen CH; Eng HL; Huang WT
BMC Cancer; 2017 Jun; 17(1):395. PubMed ID: 28576144
[TBL] [Abstract][Full Text] [Related]
8. Mitochondrial serine hydroxymethyltransferase 2 is a potential diagnostic and prognostic biomarker for human glioma.
Wang B; Wang W; Zhu Z; Zhang X; Tang F; Wang D; Liu X; Yan X; Zhuang H
Clin Neurol Neurosurg; 2017 Mar; 154():28-33. PubMed ID: 28107674
[TBL] [Abstract][Full Text] [Related]
9. MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways.
Tiemin P; Fanzheng M; Peng X; Jihua H; Ruipeng S; Yaliang L; Yan W; Junlin X; Qingfu L; Zhefeng H; Jian L; Zihao G; Guoxing L; Boshi S; Ming Z; Qinghui M; Desen L; Lianxin L
J Hepatol; 2020 Apr; 72(4):761-773. PubMed ID: 31837357
[TBL] [Abstract][Full Text] [Related]
10. The expression and clinical significance of serine hydroxymethyltransferase2 in gastric cancer.
Shan Y; Liu D; Li Y; Wu C; Ye Y
PeerJ; 2024; 12():e16594. PubMed ID: 38188143
[TBL] [Abstract][Full Text] [Related]
11. Proteomic profiling of breast cancer metabolism identifies SHMT2 and ASCT2 as prognostic factors.
Bernhardt S; Bayerlová M; Vetter M; Wachter A; Mitra D; Hanf V; Lantzsch T; Uleer C; Peschel S; John J; Buchmann J; Weigert E; Bürrig KF; Thomssen C; Korf U; Beissbarth T; Wiemann S; Kantelhardt EJ
Breast Cancer Res; 2017 Oct; 19(1):112. PubMed ID: 29020998
[TBL] [Abstract][Full Text] [Related]
12. Positive correlation between expression level of mitochondrial serine hydroxymethyltransferase and breast cancer grade.
Yin K
Onco Targets Ther; 2015; 8():1069-74. PubMed ID: 25999742
[TBL] [Abstract][Full Text] [Related]
13. Roles of Mitochondrial Serine Hydroxymethyltransferase 2 (SHMT2) in Human Carcinogenesis.
Zeng Y; Zhang J; Xu M; Chen F; Zi R; Yue J; Zhang Y; Chen N; Chin YE
J Cancer; 2021; 12(19):5888-5894. PubMed ID: 34476002
[TBL] [Abstract][Full Text] [Related]
14. Mitogen-activated protein kinase kinase kinase 4 deficiency in intrahepatic cholangiocarcinoma leads to invasive growth and epithelial-mesenchymal transition.
Yang LX; Gao Q; Shi JY; Wang ZC; Zhang Y; Gao PT; Wang XY; Shi YH; Ke AW; Shi GM; Cai JB; Liu WR; Duan M; Zhao YJ; Ji Y; Gao DM; Zhu K; Zhou J; Qiu SJ; Cao Y; Tang QQ; Fan J
Hepatology; 2015 Dec; 62(6):1804-16. PubMed ID: 26340507
[TBL] [Abstract][Full Text] [Related]
15. Multiplexed gene expression profiling identifies the FGFR4 pathway as a novel biomarker in intrahepatic cholangiocarcinoma.
Yoo C; Kang J; Kim D; Kim KP; Ryoo BY; Hong SM; Hwang JJ; Jeong SY; Hwang S; Kim KH; Lee YJ; Hoeflich KP; Schmidt-Kittler O; Miller S; Choi EK
Oncotarget; 2017 Jun; 8(24):38592-38601. PubMed ID: 28445152
[TBL] [Abstract][Full Text] [Related]
16. Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma.
Ding GY; Ma JQ; Yun JP; Chen X; Ling Y; Zhang S; Shi JY; Chang YQ; Ji Y; Wang XY; Tan WM; Yuan KF; Yan B; Zhang XM; Liang F; Zhou J; Fan J; Zeng Y; Cai MY; Gao Q
J Hepatol; 2022 Mar; 76(3):608-618. PubMed ID: 34793865
[TBL] [Abstract][Full Text] [Related]
17. A Myeloid Signature-Based Nomogram Predicts the Postoperative Recurrence of Intrahepatic Cholangiocarcinoma.
Liang J; Zhou H; Huang XQ; Liu YF; Zhang L; He D; Cui Y; Guo J; Hu K; Wu C
Front Mol Biosci; 2021; 8():742953. PubMed ID: 34722632
[TBL] [Abstract][Full Text] [Related]
18. Recurrent Amplification at 13q34 Targets at CUL4A, IRS2, and TFDP1 As an Independent Adverse Prognosticator in Intrahepatic Cholangiocarcinoma.
Liu TT; You HL; Weng SW; Wei YC; Eng HL; Huang WT
PLoS One; 2015; 10(12):e0145388. PubMed ID: 26684807
[TBL] [Abstract][Full Text] [Related]
19. SHMT2 Drives the Progression of Colorectal Cancer by Regulating UHRF1 Expression.
Cui X; Cui Y; Du T; Jiang X; Song C; Zhang S; Ma C; Liu Y; Ni Q; Gao Y; Wang G
Can J Gastroenterol Hepatol; 2022; 2022():3758697. PubMed ID: 35211429
[TBL] [Abstract][Full Text] [Related]
20. Silencing SHMT2 inhibits the progression of tongue squamous cell carcinoma through cell cycle regulation.
Liao Y; Wang F; Zhang Y; Cai H; Song F; Hou J
Cancer Cell Int; 2021 Apr; 21(1):220. PubMed ID: 33863325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
